113 related articles for article (PubMed ID: 8852442)
1. MIB1 growth fraction is not related to prognosis in cervical squamous cell carcinoma treated with radiotherapy.
Oka K; Arai T
Int J Gynecol Pathol; 1996 Jan; 15(1):23-7. PubMed ID: 8852442
[TBL] [Abstract][Full Text] [Related]
2. High growth fraction at 9 grays of radiotherapy is associated with a good prognosis for patients with cervical squamous cell carcinoma.
Oka K; Suzuki Y; Nakano T
Cancer; 2000 Oct; 89(7):1526-31. PubMed ID: 11013367
[TBL] [Abstract][Full Text] [Related]
3. Expression of proliferation-associated antigens in cervical carcinoma: correlations among indexes.
Oka K; Nakano T; Arai T
Pathol Res Pract; 1995 Oct; 191(10):997-1003. PubMed ID: 8838367
[TBL] [Abstract][Full Text] [Related]
4. Relative changes of MIB1 and PC10 labeling indexes in cell kinetics during radiotherapy for cervical squamous cell carcinoma.
Oka K; Nakano T; Hoshi T
Acta Oncol; 1997; 36(7):749-54. PubMed ID: 9490095
[TBL] [Abstract][Full Text] [Related]
5. Changes of Ki-67 index in squamous cell carcinoma of the cervix during the early course of radiotherapy and prediction of prognosis.
Kamer SA; Yalman D; Ozer E; Sayhan S; Hanhan M; Ozsaran A; Haydaroğlu A
Eur J Gynaecol Oncol; 2003; 24(3-4):287-92. PubMed ID: 12807242
[TBL] [Abstract][Full Text] [Related]
6. Studies on tumor proliferation using monoclonal antibody, Ki 67 and expression of p53 in cancer of the uterine cervix.
Bar JK; Harlozinska A; Markowska J; Nowak M
Eur J Gynaecol Oncol; 1996; 17(5):378-80. PubMed ID: 8933835
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of MIB1 monoclonal antibody in assessing the proliferative index in human bladder carcinoma: comparison with Ki-67 antibody.
Mazerolles C; Rishmann P; Chopin D; Popov Z; Malavaud B; Selves J; Neulat-Duga I; Bellot J; Delsol G
Histopathology; 1994 Dec; 25(6):563-8. PubMed ID: 7698733
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma.
Sittel C; Eckel HE; Damm M; von Pritzbuer E; Kvasnicka HM
Laryngoscope; 2000 Jun; 110(6):1012-7. PubMed ID: 10852523
[TBL] [Abstract][Full Text] [Related]
9. [Ki-67 expression in stage III cervical squamous cell carcinoma and its correlation with sensitivity to chemoradiotherapy].
Cheng S; Wang Z; Wang L; Zhang M
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):667-70. PubMed ID: 25564056
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the PC10 index as a prospective assay for cervical cancer treated with radiation therapy alone.
Oka K; Hoshi T; Arai T
Cancer; 1992 Sep; 70(6):1545-50. PubMed ID: 1355399
[TBL] [Abstract][Full Text] [Related]
11. p53CM1 expression is not associated with prognosis in uterine cervical carcinoma.
Oka K; Nakano T; Arai T
Cancer; 1993 Jul; 72(1):160-4. PubMed ID: 8508400
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical prediction of radiation response and local control in radiation therapy for cervical cancer.
Nakano T; Oka K; Ishikawa A; Morita S
Cancer Detect Prev; 1998; 22(2):120-8. PubMed ID: 9544432
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1. A comparison with proliferating cell nuclear antigen.
Ng IO; Na J; Lai EC; Fan ST; Ng M
Am J Clin Pathol; 1995 Sep; 104(3):313-8. PubMed ID: 7545866
[TBL] [Abstract][Full Text] [Related]
14. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.
Caly M; Genin P; Ghuzlan A A; Elie C; Fréneaux P; Klijanienko J; Rosty C; Sigal-Zafrani B; Vincent-Salomon A; Douggaz A; Zidane M; Sastre-Garau X
Anticancer Res; 2004; 24(5B):3283-8. PubMed ID: 15510624
[TBL] [Abstract][Full Text] [Related]
15. [Importance of determination of proliferation markers and hormone receptors in breast carcinoma].
Skálová A; Michal M
Cas Lek Cesk; 1997 Jul; 136(15):473-8. PubMed ID: 9340194
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.
Pinder SE; Wencyk P; Sibbering DM; Bell JA; Elston CW; Nicholson R; Robertson JF; Blamey RW; Ellis IO
Br J Cancer; 1995 Jan; 71(1):146-9. PubMed ID: 7819031
[TBL] [Abstract][Full Text] [Related]
17. Cytoplasmic p105 index is an accurate mitotic index, but is not related to prognosis in cervical carcinoma.
Oka K; Nakano T; Arai T
Arch Pathol Lab Med; 1994 May; 118(5):506-9. PubMed ID: 7910727
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies Ki-67 and MIB1 in the distinction of tuboendometrial metaplasia from endocervical adenocarcinoma and adenocarcinoma in situ in formalin-fixed material.
McCluggage WG; Maxwell P; McBride HA; Hamilton PW; Bharucha H
Int J Gynecol Pathol; 1995 Jul; 14(3):209-16. PubMed ID: 8600071
[TBL] [Abstract][Full Text] [Related]
19. MIB 1 immunostaining in stage I squamous cervical carcinoma: relationship with natural killer cell activity.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de Nictolis M; Muzzioli M; Fabris N; Romanini C; Biagini G
Gynecol Oncol; 1995 Jul; 58(1):28-33. PubMed ID: 7789886
[TBL] [Abstract][Full Text] [Related]
20. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies.
Abele MC; Valente G; Kerim S; Navone R; Onesti P; Chiusa L; Resegotti L; Palestro G
Haematologica; 1997; 82(3):281-5. PubMed ID: 9234572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
